<DOC>
	<DOC>NCT01277094</DOC>
	<brief_summary>This multi-center, double-blind, randomized, placebo-controlled study will evaluate the change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with non-alcoholic fatty liver disease. Patients will be randomized to receive either daily oral doses of RO5093151 or matching placebo. The anticipated time on study treatment is 12 weeks.</brief_summary>
	<brief_title>A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult patients, 3565 years of age Hepatic steatosis assessed by magnetic resonance spectroscopy (MRS) with liver fat &gt;5.56% at screening Body mass index (BMI) &gt;27 kg/m2 at screening Insulin resistance assessed by homeostatic model assessmentinsulin resistance (HOMAIR) &gt; 2.5 at screening Agreement to maintain prior diet and exercise habits during the full course of study History of diabetes mellitus based on World Health Organization (WHO) criteria Known polycystic ovary syndrome Other liver disease e.g. chronic viral hepatitis, alcoholic liver disease, hemachromatosis, cirrhosis Known autoimmune disease or chronic inflammatory disease Myocardial infarction or stroke within 6 months prior to screening Patients taking any antidiabetic and/or weightlowering medication currently or within the previous 3 months before screening</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>